It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
January 31, 2019
- Kymriah Study Drugs to Be Manufactured in Kobe: Novartis
January 30, 2019
- Stem Cell Therapy SB623 Misses Key Target in US PIIb Study for Stroke: SanBio, Sumitomo Dainippon
January 30, 2019
- Protosera, Fujita Health Univ. Tie Up for Research to Develop Treatments for Autism Spectrum Disorder
January 30, 2019
- China Approves Latuda for Schizophrenia: Sumitomo Dainippon
January 30, 2019
- Takeda to Book 38 Billion Yen Gain from Sale of Osaka HQ, Other Assets
January 29, 2019
- Ex-MHLW Bureau Chief Takeda Tapped as Senior Adviser at BCG
January 29, 2019
- Nippon Express to Set Up 4 Distribution Centers for Full-Scale Drug Logistics Biz, Aims for 15 Billion Yen Annual Sales
January 29, 2019
- Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show
January 28, 2019
- Tamiflu Generics, Too, in Tight Supply amid Spike in Flu Patients
January 28, 2019
- Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
January 25, 2019
- Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing
January 25, 2019
- Shionogi, PeptiDream Join Forces for Novel Peptide Drug-Conjugate Discovery Research
January 24, 2019
- Mitsubishi Tanabe Shooting for 100 Billion Yen Sales in US/Europe, 50% Overseas Ratio
January 23, 2019
- Astellas to Transfer Dormicum to Maruishi
January 23, 2019
- Astellas, Kaketsuken Successor End Vaccine, Blood Product Pact
January 23, 2019
- SanBio’s Cell Therapy to Be Developed for Brain Bleeding Too
January 22, 2019
- Shionogi Upping Xofluza Production to Get Back to Normal before Flu Season Ends
January 22, 2019
- Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief
January 22, 2019
- Janssen, Nippon Shinyaku to Copromote Prostate Cancer Treatment Apalutamide in Japan
January 22, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…